Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — CollPlant Holdings — Investor Presentation (September 2018)
27 slides from Collplant Biotechnologies's investor presentation, Sep 6, 2018
Slide 1: Corporate presentation: Revolutionizing Tissue Repair
Gj CollPlant Revolutionizing Tissue Repair Lt Corporate presentation Yehiel Tal, CEO ) September 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21£ of the Securities Exchange Act and are usually identified by the use of words such as “anticipates,” "believes," "estimates,"
Slide 3: Overview
Overview @ Regenerative medicine company developing and commercializing tissue repair products Proprietary technology enables the cost- efficient production of high-quality recombinant human collagen (rhCollagen) Products initially aimed at 3D Bioprinting, orthobiologics, advanced wound care and med
Slide 4: Experienced management team
Experienced management team Prof. Oded Shoseyov Co-Founder & CSO Pauli Clean Tech CBD Tech. Fulcrum-SPD Melodea Hebrew University a i Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Nadav Orr, PhD Revital Mandil-Levin, PhD, MBA VP R&D Chief Business Officer Ethicon Bi
Slide 5: Technology platform
Technology platform FcolPiant Revolutionizing Tissue Repair
Slide 6: CollPlant's technology
CollPlant’s technology Co-expression of 5 human genes in tobacco plants for the production of functional type | human recombinant Collagen Tobacco plant Tobacco plant 4 %~-4)e » tte. se Stable production Structural géfies Enzyme gefies in tobacco plant ees re a LH-3 Post translational modifications
Slide 7: CollPlant's technology: Cost effective and scalable production
CollPlant’s technology: Cost effective and scalable production Plant Leaves Protein Concentrate Collagen PLANTLETS ) (>) (0) PURIFICATION 0) END PRODUCT IN NURSERY Se OW ING ‘ EXTESCUON & FILLING FABRICATION 5 — - f (7) FcoltPiant Worescoiing tse aoa
Slide 8: Plant-derived rhCollagen
Plant-derived rhCollagen Clear advantages over animal-derived collagen * Accelerates human cell proliferation Faster tissue healing * Controlled physical/rheological properties * Reproducibility ¢ Transparency (not visible) * Non-immunogenic * Non-allergenic *No pathogens *No foreign body response A
Slide 9: Business overview
Business overview * Organs 3D Aesthetic * Co-development * Tissues bioprinting* medicine * In house 1st GEN dermal filler * Scaffolds * In house 2" GEN dermal filler ¢ EU distribution via ¢ EU distribution Arthrex * Applying for US FDA Orthobiolosi Advanced rthobiologics approval 8 wound care ¢ Post
Slide 10: BioInk
Biolnk for 3D bioprinting of organs, tissues & scaffolds (FcollPlant Revolutionizing Tissue Repalr
Slide 11: Average transplant costs and wait times in USA
Average transplant costs and wait times in USA: HEART (2,725/YEAR) KIDNEY (16,804/YEAR) $1.4 million $415,000 191 days 679 days LUNGS (1,397/YEAR) PANCREAS (136/YEAR) $1.2 million $347,000 185 days 281 days LIVER (6,158/YEAR) CORNEA (50,099/YEAR) $813,000 $30,200 239 days 50 days The advent of 3D bi
Slide 12: rhCollagen BioInk for 3D printing of tissues and organs
a t rhCollag Biolnk for 3D printing of ui issues and organs CollPlant’s rhCollagen-based Biolnk offers ideal characteristics for 3D bioprinting Optimal rheology at room Biocompatible — temperature - Viscosity and supports viability of gelation kinetics different cell types DOMIMMUROREnIC) a Tunable
Slide 13: rhCollagen BioInk
rhCollagen Biolnk Compositions in development (with partners/collaborators) Direct Ink Writing (DIW) Additives (Synthetic/Natural) Cells ————° : I. . GFcoltPtant ——— Biolnk oo 20m Chemical modifications Projection Stereolithography Laser Induced Forward Growth Factors ———® o Transfer (LIFT) (13) Col
Slide 14: BioInk business segments
Biolnk business segments Tissues ey Skin, cornea, bones, cartilage, blood vessels, heart valves Collaborations* Organs Lungs, liver, kidney, heart, pancreas Scaffolds Spine fusion, extremities, craniomaxillofacial, tendons, ligaments Collaborations* In-house development CollPlant ang Tse pak (14) *
Slide 15: Aesthetic medicine
Aesthetic medicine Regenerative dermal filler (A collPlant Revolutionizing Tissue Repalr
Slide 16: Combining the advantages of Collagen and Hyaluronic Acid
Combining the advantages of Collagen and Hyaluronic Acid Physical properties * Highly viscous: Provides mechanical stability after injection * Convenient injection: 37-32G needle, 10-15N expression force rhCollagen Biological properties * Promotes cell adhesion and j proliferation 1 » Promotes tissu
Slide 17: 2nd Gen dermal filler: Photocurable rhCollagen-HA
24 Gen dermal filler: Photocurable rhCollagen-HA for facial aesthetics Injectable Photo-curable methacrylate-rhCollagen for in-situ photocuring Injection Sculpturing Photocuring in-situ \ ¢rhCollagen { inside ON (stabilization) © PFcolpiant
Slide 18: Commercial products
Commercial products 3D Bioprinting, Advanced Wound Care, Orthobiologics )) Verges [3cc | ) Vergentx-rs Ea Wound Finer (A collPlant Revolutionizing Tissue Repalr
Slide 19: VergenixSTR Orthobiologics
‘ Vergen)x”stR Orthobiologics Soft Tissue Repair PRP collection tube from any commercial PRP Kit Platelet-Rich Plasma ) Red Blood Cells a cE marked @ Intended for treatment of tendinopathy e Provides: - Localization of platelets at the injury site - Extended therapeutic effect of growth factors e As
Slide 20: Clinical study: VergenixSTR clinical outcomes
Clinical study PMs** é e e Vergen)x"sTR Clinical outcomes Significant advantages over standard of care 86% + 40 patients, single arm, single treatment, 3 & 6 month f/u of patients show clinical success at 6M 74% of patients show clinical success at 3M + End points — Safety; recovery in pain and moti
Slide 21: VergenixFG Wound care
0.9% Sodium Chloride: Injection, USP U Vergen)x"FG Wound care e rhCollagen wound filler intended for the management of acute and chronic wounds | ‘ F 5 _ CE marked all e Use in OR and in outpatient clinics e Single application treatment BENEFITS e Commercialization commenced by local ivolgds =) | Ge
Slide 22: VergenixFG Clinical outcomes
é e e Vergen)x"FG Clinical outcomes 75% average wound closure after 1 month (single treatment); 93% average wound closure after 4 months 100% Average wound size reduction over time (N= 56) 80% 90% 93% 9 60% 15% AUS 40% 20% 0% Month 1 Month 2 Month 3 Month 4 79% clinically significant wound closure*
Slide 23: KOL Testimonials
KOL Testimonials HOSPITAL FOR ‘SPECIAL SURGERY D7 iN Joseph Lane, MD Professor of Orthopaedic Surgery, Weill Cornell Medical College Attending Orthopaedic Surgeon, Hospital for Special Surgery “Now we have available a human collagen that is arrayed completely and naturally with no abnormal partial l
Slide 24: Development: Planned upcoming milestones
Development Commercial Planned upcoming milestones BioInk - Signing license agreement for organ/tissue bioprinting - Expand our Biolnk collaborations Aesthetics - POC study with rhCollagen-HA dermal filler VergenixSTR - Pre-Submission meeting with FDA - Expand EU market penetration VergenixFG - Expa
Slide 25: Financial & HR position
Financial & HR position NASDAQ (CLGN) listed ADR Funds raised 40 employees since January 2018 to-date * Strong R&D team + Market Cap of ~ $20M (Aug 22, 2018) ~ $68M * Fully integrated * Production team with seven years track record ¢ Upscaling production capacity & capabilities in 2018 * TASE delist
Slide 26: CollPlant investment highlights
CollPlant investment highlights Only commercially viable technology Broadly applicable technology: currently available that can produce Ideal building block/scaffolding truly human collagen molecule for regenerative medicine Multi-billion dollar market: innovative rhCollagen products initially aimed
Slide 27: Thank you
(ffcollPlant XS Revolutionizing Tissue Repair ow Thank you
CollPlant Holdings — Investor Presentation (September 2018) on 6ix